Sponsors (10)
The bill improves infant‑formula safety, outbreak response, and supply transparency through faster reporting and oversight, but it raises compliance and administrative costs and could cause short‑term supply disruptions or higher prices for families.
Parents, caregivers, and infants will get faster notification, mandatory FDA response timelines, and required sharing of isolate/genetic data so contaminated formula is identified and removed more quickly, reducing illness and enabling faster outbreak control.
Parents, caregivers, and health providers gain better visibility into infant formula availability through an initial (270‑day) and quarterly supply‑chain reporting schedule plus improved interagency coordination, which can help prevent or mitigate shortages and make it easier to find needed product.
Taxpayers and consumers benefit from increased regulatory transparency and accountability—required FDA response timelines, stakeholder reviews, and reporting to Congress could surface implementation gaps and lead to additional resources or authorities to strengthen long‑term market resiliency.
Parents, low‑income families, and hospitals face a higher risk of short‑term formula shortages or local unavailability because faster mandatory reporting and follow‑up can trigger more frequent recalls or production halts, and FDA capacity constraints could exacerbate disruptions.
Small and large infant formula manufacturers will incur higher testing, reporting, and compliance costs (including possible new recommended practices), which may be passed on to consumers as higher retail prices, disproportionately affecting parents and low‑income households.
More frequent reporting and stakeholder processes impose additional administrative costs on FDA and could require more resources or divert staff from inspections and other functions, creating tradeoffs in agency priorities funded by taxpayers.
Based on analysis of 3 sections of legislative text.
Requires 1‑business‑day manufacturer notification and FDA response for confirmed microbial contamination in finished infant formula and creates new FDA reporting and supply‑chain oversight duties.
Introduced January 28, 2025 by Gary C. Peters · Last progress April 28, 2026
Requires infant formula manufacturers to notify the FDA within 1 business day after a confirmed positive test for any regulated microorganism in finished product, to consult with FDA, to provide test results and isolates or whole genetic sequences, and to stop distribution and dispose of affected lots if directed. Directs the FDA to respond within 1 business day, confirm that manufacturers perform appropriate investigations and corrective actions within 90 days, and to inspect or obtain documentation as needed. Also requires the FDA to produce a series of reports and consultations to improve infant formula safety and supply resilience: a 180‑day progress report on implementing its long‑term strategy, regular supply‑chain reports (starting within 270 days and then quarterly for five years) to congressional committees, interagency engagement with USDA and others, and stakeholder reviews and recommendations at 1, 3, and 5 years after enactment.